Exclusive

Publication

Byline

Singapore Clinical Trial: A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the effi... Read More


Singapore Clinical Trial: A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab A... Read More


Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus and Participants with Overweight or Obesity without Type 2 Diabetes Mellitus.

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Ret... Read More


Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus and Participants with Overweight or Obesity without Type 2 Diabetes Mellitus.

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Ret... Read More


Singapore Clinical Trial: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination Wi... Read More


Singapore Clinical Trial: EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate ... Read More


దక్షిణ మధ్య రైల్వేకు రూ.21,211.92 కోట్ల ఆదాయం.. జోన్‌ చరిత్రలోనే రికార్డు స్థాయి

భారతదేశం, ఏప్రిల్ 2 -- దక్షిణ మధ్య రైల్వే 2025-2026 ఆర్థిక సంవత్సరానికిగాను రూ.21,211.92 కోట్ల అత్యధిక ఆదాయాన్ని సాధించింది. ఇది గత ఏడాదితో పోలిస్తే 3.12 శాతం పెరుగుదలను సూచిస్తుంది. ఈ రికార్డు స్థాయి... Read More


RBI announces more actions amid rupee depreciation

Mumbai, April 2 -- Amid sharp depreciation in the rupee, the Reserve Bank on Wednesday announced more actions focused on authorised dealers (ADs). On a review of evolving market conditions, it has bee... Read More


Assistant to bus driver dies after falling off moving bus in Noakhali

Dhaka, April 2 -- A bus driver's assistant has died after falling off a moving bus in Noakhali Sadar. The accident took place in the Maijdi Bazar area of the Chaumuhani-Maijdi road on Wednesday night... Read More


Chemical stocks tumble as duty cuts trigger margin fears

Mumbai, April 2 -- The selloff was sharp across the board. Among the key losers, Swan Energy fell 5.61%, SRF declined 5.53%, Navin Fluorine International dropped 4.79%, Coromandel International slippe... Read More